Medigen Vaccine Biologics Corp (高端疫苗) is to receive a subsidy of US$2.3 million from the international Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a clinical trial in Taiwan to test its COVID-19 vaccine as a booster shot following full immunization with other brands, it said on Thursday. The company plans to begin the trial once it is approved by the Food and Drug Administration, and aims to conduct an interim analysis by the end of March next year, it said. The trial would be a “mix-and-match” type to test the safety and immunogenicity of different combinations of multiple brands of COVID-19